Stockreport

New Efficacy Data for Non-Clear Cell Renal Cell Carcinoma From KEYNOTE-B61 Added to LENVIMA® (lenvatinib) US Label Supporting KEYTRUDA + LENVIMA Indication for the First-Line Treatment of ...

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF NUTLEY, N.J. June 27, 2024 /PRNewswire/ -- Eisai today announced a label update for LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered [Read more]